5a-DHT

If you have ever wondered why two people with identical testosterone levels can have wildly different experiences with hair thinning, prostate symptoms, or skin oiliness, the answer often lies downstream. Your body converts testosterone into a more potent androgen, and how much of that conversion happens shapes a lot of what you actually feel.

This test looks at DHT (dihydrotestosterone) and its breakdown products in a urine sample dried onto a collection card. It is an exploratory window into how your body processes androgens over the course of a day, rather than a single snapshot in the blood.

What This Test Actually Captures

DHT is the 5-alpha-reduced metabolite of testosterone, made in tissues like the prostate, skin, liver, and hair follicles by enzymes called 5-alpha-reductases. It binds androgen receptors more strongly than testosterone itself (forming a more stable receptor complex because DHT dissociates from the receptor more slowly) and is required for full external male genital development.

A dried urine measurement reflects how your body is metabolizing androgens through the 5-alpha-reduction pathway, captured as DHT and related steroid byproducts excreted in urine. This is different from a blood DHT level, which measures what is circulating at one moment. Urine averages excretion over a collection window and is heavily shaped by the urinary metabolites your body produces, not just DHT itself.

One important caveat lives in the biology. Much of the DHT made inside tissues like the prostate is broken down locally before it ever enters the bloodstream or the urine. Clinical studies show that intracellular androgen levels in androgen-sensitive tissues are essentially independent of circulating androgen levels. So while this test can hint at how actively your body is running the testosterone-to-DHT conversion, it does not directly measure androgen activity inside any specific organ.

Where This Marker Sits on the Evidence Map

5-alpha-DHT in dried urine is a research-grade, exploratory marker. Standardized clinical cutpoints do not exist, and most of the published evidence on urinary androgens comes from conventional liquid urine collection analyzed by mass spectrometry, not dried urine cards. The strongest available studies use urinary steroid ratios involving DHT and its metabolites to investigate androgen exposure, diagnose enzyme deficiencies, or monitor anabolic steroid use, not to assess routine health risk in the general population.

That does not mean the number is meaningless. It means you should treat your result as one data point inside a wider androgen picture, not a stand-alone verdict on your health. A single value will rarely answer a clinical question on its own.

5-Alpha-Reductase Deficiency

The clearest disease association for this pathway is 5-alpha-reductase deficiency, an inherited condition where the enzyme that converts testosterone to DHT does not work properly. Affected individuals (typically 46,XY) show low DHT, an elevated testosterone-to-DHT ratio, and abnormal urinary ratios of 5-alpha to 5-beta steroid metabolites. Because DHT is required for full external masculinization, severe deficiency typically presents with ambiguous external genitalia at birth.

In a single validation study of Vietnamese children, a urinary 5-alpha-tetrahydrocortisol to tetrahydrocortisol ratio at a cutoff of 0.19 reportedly detected the deficiency with 100% sensitivity and 100% specificity in boys aged 6 months to 13 years. That is unusually strong performance and supports random urine steroid analysis as a first-line test in this specific setting, though these results come from one cohort and may not generalize to all populations or age groups.

Prostate Biology and the Limits of Inference

It is tempting to assume that higher DHT must mean more prostate disease. The preponderance of evidence does not support that conclusion. A comprehensive endocrine review and several large prospective studies found that modest elevations in circulating DHT have not been linked to increased risk of prostate cancer or benign prostatic hyperplasia. The cardiovascular evidence is less uniform: while modest DHT elevations have not generally been tied to adverse cardiovascular signals, the Cardiovascular Health Study found a curvilinear (U-shaped) association between DHT and incident cardiovascular disease and all-cause mortality in older men.

Researchers have hypothesized that genetic variants leading to higher 5-alpha-reductase activity inside prostate tissue might raise prostate cancer risk, and metastatic prostate cancers do show altered expression of the enzymes that make DHT. But these are tissue-level findings. They do not translate cleanly into a rule that a higher urinary DHT result on your report means a higher cancer risk for you.

Why both findings can be true at the same time: this is not a simple good number versus bad number marker. It is an indicator of how your body is processing androgens, and the same pathway means different things in different contexts. A low value can signal an inherited enzyme problem in one person and reflect normal variation in another. A high value can flag exogenous androgen use or strong endogenous conversion without indicating any disease. The number is most useful when interpreted alongside the rest of your androgen profile and your clinical situation.

Hair, Skin, and Visible Androgen Effects

DHT is the main androgen driving male-pattern hair loss, sebum production, and adult body hair patterns. The enzymes that produce it are concentrated in skin and hair follicles. That biology is what makes 5-alpha-reductase inhibitors effective treatments for androgenic hair loss.

The supplied evidence does not, however, link a specific dried urine DHT level to a probability of developing or worsening hair loss, acne, or oily skin. So while the biology is real, the test does not have validated thresholds that say at what value these effects become more likely.

Detection of Androgen Exposure

Urinary DHT measurements have an established role in detecting exogenous androgen use. In six healthy men given a single intramuscular dose of DHT heptanoate (250 mg), urinary DHT-to-epitestosterone and 5-alpha-androstanediol-to-epitestosterone ratios rose far above population reference limits within 24 hours and stayed elevated for 10 to 14 days, returning to baseline by day 28. In another study, an oral 50 mg dose of DHT produced an intense but short signal that normalized within about 24 hours.

For you, this means a recent course of testosterone replacement, DHT-containing therapy, or anabolic steroids can dramatically shift your urinary DHT and related ratios. If your level is unexpectedly high, that history matters more than the number itself.

Why a Single Reading Can Mislead

Several factors can throw off a single dried urine androgen result, and the supplied literature flags a few worth knowing about:

• Recent androgen exposure: testosterone gel, injectable testosterone, DHT preparations, anabolic steroids, and even some over-the-counter prohormones can spike urinary DHT and related ratios for days to weeks after a single dose.
• 5-alpha-reductase inhibitors: drugs like finasteride (which lowers serum DHT by roughly 70%) and dutasteride (which lowers it by roughly 90 to 95%) suppress the conversion of testosterone to DHT. They will lower your reading without indicating any underlying disease.
• Hormonal cycle in women: in a study of 14 women using testosterone gel, menstrual-cycle fluctuations in epitestosterone disrupted the sensitivity of urinary androgen ratios, making single readings hard to interpret.
• Collection technique: dried urine collection requires saturating the card at the right time of day and letting it dry fully. Skipping a sample, contaminating the card, or shipping a damp card can distort results.

Why One Reading Is Not Enough

For a research-grade marker without standardized cutpoints, a single value is at best a starting point. Hormone metabolism varies day to day with sleep, stress, training, and supplement intake. Trending matters more than any one number, and it matters even more when you are making changes you expect to influence androgens, such as starting a 5-alpha-reductase inhibitor, beginning hormone therapy, or trying a supplement marketed to support DHT levels.

A practical cadence is to establish a baseline, repeat in 3 to 6 months if you are making interventions, and continue at least annually if you are tracking the pathway over time. Compare your own trajectory rather than benchmarking against population numbers that may not have been validated for the assay your lab uses.

Decision Pathway for Unexpected Results

An out-of-pattern result on this test is best read alongside a broader androgen panel, not in isolation. If your dried urine DHT is low or your testosterone-to-DHT relationship looks unusual, useful next steps include checking serum total and free testosterone, serum DHT, sex hormone binding globulin, and the full DUTCH-style metabolite profile if you have not already. Together, those provide context on whether the issue is low testosterone production, slowed conversion to DHT, or a measurement artifact.

If your result is high and you have visible androgen effects like accelerated hair loss, severe acne, or prostate-related symptoms, the pathway typically involves correlating with a serum DHT, reviewing any androgen-active medications or supplements, and considering whether a urologist (for prostate concerns) or endocrinologist (for broader hormone questions) should be in the loop. If a genetic enzyme disorder is suspected based on developmental or family history, a clinician familiar with disorders of sex development can guide confirmatory testing.

What you are looking for is a coherent pattern across multiple labs and your own symptoms, not a single threshold to act on.